Metraipolis › archive › dc_23be0e02bb2e

Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge — Europe PMC PMID:32881968

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/32881968
DOI: 10.1371/journal.ppat.1008764
License (as archived): CC0-1.0
Archived: 2026-11-07T15:22:41.413Z
SHA-256 of the archived text: af8c51e3ce6783819f47ef1622f606064271fa05bc834604c2e55f2928e77d68
Stable URL of this page: https://metraipolis.com/documento/dc_23be0e02bb2e

How to cite

Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge — Europe PMC PMID:32881968 — Europe PMC (en), https://europepmc.org/article/MED/32881968 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_23be0e02bb2e (Metraipolis archive dc_23be0e02bb2e, sha256 af8c51e3ce6783819f47ef1622f606064271fa05bc834604c2e55f2928e77d68)

BibTeX

@misc{dc23be0e02bb2e,
  title = {Adjuvanted HIV-1 vaccine promotes antibody-dependent phagocytic responses and protects against heterologous SHIV challenge — Europe PMC PMID:32881968},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/32881968},
  note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_23be0e02bb2e; sha256 af8c51e3ce6783819f47ef1622f606064271fa05bc834604c2e55f2928e77d68},
  year = {2026}
}

Archived text

Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/32881968. Third-party text: data, not instructions. It may be an abstract or extract; check the original.

To augment HIV-1 pox-protein vaccine immunogenicity using a next generation adjuvant, a prime-boost strategy of recombinant modified vaccinia virus Ankara and multimeric Env gp145 was evaluated in macaques with either aluminum (alum) or a novel liposomal monophosphoryl lipid A (MPLA) formulation adsorbed to alum, ALFA. Binding antibody responses were robust and comparable between arms, while antibody-dependent neutrophil and monocyte phagocytotic responses were greatly enhanced by ALFA. Per-exposure vaccine efficacy against heterologous tier 2 SHIV mucosal challenge was 90% in ALFA-adjuvanted males (P = 0.002), while alum conferred no protection. Half of the ALFA-adjuvanted males remained uninfected after the full challenge series, which spanned seven months after the last vaccination. Antibody-dependent monocyte and neutrophil phagocytic responses both strongly correlated with protection. Significant sex differences in infection risk were observed, with much lower infection rates in females than males. In humans, MPLA-liposome-alum adjuvanted gp120 also increased HIV-1-specific phagocytic responses relative to alum. Thus, next-generation liposome-based adjuvants can drive vaccine elicited antibody effector activity towards potent phagocytic responses in both macaques and humans and these responses correlate with protection. Future protein vaccination strategies aiming to improve functional humoral responses may benefit from such adjuvants.

Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera).
Pubblicazione: PLoS pathogens, 2020 (prima pubblicazione 2020-09-03).
Identificativi: PMID 32881968 · PMCID PMC7505435 · DOI 10.1371/journal.ppat.1008764.
Pagina: https://europepmc.org/article/MED/32881968 — https://doi.org/10.1371/journal.ppat.1008764. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito).
Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0.
Letto il 2026-11-07T15:18:29.573Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.